KR910020036A - 펜사이클리딘 및 펜사이클리딘 대사체 검정법, 트레이서, 면역원, 항체 및 시약 키트 - Google Patents

펜사이클리딘 및 펜사이클리딘 대사체 검정법, 트레이서, 면역원, 항체 및 시약 키트 Download PDF

Info

Publication number
KR910020036A
KR910020036A KR1019910008927A KR910008927A KR910020036A KR 910020036 A KR910020036 A KR 910020036A KR 1019910008927 A KR1019910008927 A KR 1019910008927A KR 910008927 A KR910008927 A KR 910008927A KR 910020036 A KR910020036 A KR 910020036A
Authority
KR
South Korea
Prior art keywords
compound
nitrogen
heteroatoms
sample
pencyclidine
Prior art date
Application number
KR1019910008927A
Other languages
English (en)
Inventor
에드워드 두블러 로버트
그로트 조나단
제임스 혹스워쓰 데이비드
에스. 남 다니엘
케이 레이 레리
패트 프린트너 메리
앨렌 하들리 그레그
데이톤 홉킨스 할
에스. 언게마치 프랭크
Original Assignee
챨스 엠. 브록
애보트 래보러토리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 챨스 엠. 브록, 애보트 래보러토리즈 filed Critical 챨스 엠. 브록
Publication of KR910020036A publication Critical patent/KR910020036A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/816—Alkaloids, amphetamines, and barbiturates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Luminescent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

펜사이클리딘 및 펜사이클리딘 대사체 검정법, 트레이서, 면역원, 항체 및 시약 키트
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. 하기 일반식의 화합물.
    상기식에서, W는 CH 또는 질소이고; R는 헤테로원자수가 4이하이며, 직쇄 또는 측쇄에 배열된 탄소원자 및 헤테로원자의 총수가 0 내지 8이고 1개 이하의 지방족 또는 방향족 환 구조를 갖는 결합 그룹이며 (여기서, 헤테로 원자는 산소, 질소, 황, 인 또는 불소이다), Z은 NH, CO 또는 CNH이고; N은 W가 질소인 경우 0 또는 1이며, W가 CH인 경우 1이고; Q는 폴리(아미노산) 또는 폴리(아미노산) 유도체이다.
  2. 제1항에 있어서, 하기 일반식(23)의 화합물.
  3. 제2항에 있어서, 폴리(아미노산)이 티로글로불린인 화합물.
  4. 제1항, 제2항 또는 제3항에 따른 화합물에 대한 항체.
  5. 하기 일반식의 화합물.
    W는 CH 또는 질소이고; R은 헤테로원자수가 4이하이며, 직쇄 또는 측쇄에 배열된 탄소원자 및 헤테로원자의 총수가 0 내지 8이고 1개 이하의 지방족 또는 방향족 환 구조를 갖는 결합 그룹이며 (여기서, 헤테로원자는 산소, 질소, 황, 인 또는 불소이다); Z은 NH, CO 또는 CNH이고; n은 W가 질소인 경우 0 또는 1이며, W가 CH인 경우 1이고; Q는 플루오레스세인(fluorescein) 또는 그의 유도체이다.
  6. 제5항에 있어서, R이 NH인 화합물.
  7. 제5항 또는 제6항에 있어서, Z이 CO인 화합물.
  8. 제5항에 있어서, 하기 구조식(14)의 화합물.
  9. (a) 샘플을 제4항에 따른 항체 및 제5항에 따른 화합물과 접촉시키는 단계; (b) 단계(a)로부터 수득한 용액에 면 편광(plane polarized light)을 통과시켜 형광 편광 반응(fluorescence polarization response)을 수득하는 단계; 및 (c) 단계(b)의 용액의 형광 편광 반응을 샘플 중 펜사이클리딘(phencylidine) 및/또는 펜사이클리딘 대사체의 존재 및 양의 측정치로서 검출하는 단계를 포함함을 특징으로 하여, 샘플 중 펜사이클리딘 및/또는 펜사이클리딘 대사체의 존재 또는 양을 검출하는 방법.
  10. 제9항에 있어서, 추가로 리보플라빈 결합 단백질을 샘플에 가하는 단계를 포함하는 방법.
  11. 제10항에 있어서, 제4항에 따른 항체가 제3항에 따른 화합물에 대해 생성되는 방법.
  12. (a) 제4항에 따른 항체; 및 (b) 제5항에 따른 화합물을 포함함을 특징으로 하는, 샘플중 펜사이클리딘 및/또는 펜사이클리딘 대사체의 존재 또는 양을 검출하는 키트(kit).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910008927A 1990-05-29 1991-05-29 펜사이클리딘 및 펜사이클리딘 대사체 검정법, 트레이서, 면역원, 항체 및 시약 키트 KR910020036A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7/529,988 1990-05-29
US07/529,988 US5155212A (en) 1986-05-21 1990-05-29 Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit

Publications (1)

Publication Number Publication Date
KR910020036A true KR910020036A (ko) 1991-12-19

Family

ID=24112004

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910008927A KR910020036A (ko) 1990-05-29 1991-05-29 펜사이클리딘 및 펜사이클리딘 대사체 검정법, 트레이서, 면역원, 항체 및 시약 키트

Country Status (9)

Country Link
US (2) US5155212A (ko)
EP (1) EP0459387B1 (ko)
JP (1) JPH04235199A (ko)
KR (1) KR910020036A (ko)
AT (1) ATE128241T1 (ko)
AU (1) AU643524B2 (ko)
CA (1) CA2043372A1 (ko)
DE (1) DE69113114T2 (ko)
ES (1) ES2080188T3 (ko)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304479A (en) * 1991-12-06 1994-04-19 Diagnostic Reagents, Inc. Phencyclidine compounds and assays for its determination
US5233042A (en) * 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5331109A (en) * 1992-04-06 1994-07-19 Biosite Diagnostics Incorporated Phencyclidine derivatives and protein and polypeptide phencyclidine derivative conjugates and labels
US6143576A (en) * 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US6767510B1 (en) 1992-05-21 2004-07-27 Biosite, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6905882B2 (en) * 1992-05-21 2005-06-14 Biosite, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US7524456B1 (en) 1992-05-21 2009-04-28 Biosite Incorporated Diagnostic devices for the controlled movement of reagents without membranes
US6242463B1 (en) 1994-10-31 2001-06-05 Opt-E-Scrip, Inc. Method and kit for treating illnesses
CA2175862A1 (en) * 1995-05-19 1996-11-20 Roberto Sundoro Wu Propoxyphene derivatives for immunoassay reagents
US6063908A (en) * 1996-07-02 2000-05-16 Roche Diagnostics Corporation Reagents for lysergic acid diethylamide immunoassay
US7070921B2 (en) 2000-04-28 2006-07-04 Molecular Devices Corporation Molecular modification assays
US7745142B2 (en) 1997-09-15 2010-06-29 Molecular Devices Corporation Molecular modification assays
US5939332A (en) * 1998-02-27 1999-08-17 Roche Diagnostics Corp. Phencyclidine analogs for immunoassay
WO1999049831A2 (en) * 1998-03-28 1999-10-07 Martin Vladimir V Amplified fluorescent materials and uses thereof
US20040065188A1 (en) * 2001-01-12 2004-04-08 Stuebner Fred E. Self-aligning ultrasonic sensor system, apparatus and method for detecting surface vibrations
DE10112198A1 (de) 2001-03-14 2002-09-19 Gruenenthal Gmbh Substituierte Dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-ylmethyl]-amine
EP1333023B1 (en) * 2002-01-31 2010-12-22 Randox Laboratories Ltd. Immunogens, antibodies and conjugates to ketamine and its metabolites
US20110098309A1 (en) * 2007-07-12 2011-04-28 Acumen Pharmaceuticals, Inc. Methods of inhibiting the formation of amyloid-beta diffusable ligands using acylhydrazide compounds
US8962677B2 (en) * 2007-07-12 2015-02-24 Acumen Pharmaceuticals, Inc. Methods of restoring cognitive ability using non-peptidic compounds
US9006283B2 (en) * 2007-07-12 2015-04-14 Acumen Pharmaceuticals, Inc. Methods of modifying amyloid β oligomers using non-peptidic compounds
WO2009079566A2 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
CN102627696B (zh) * 2012-04-11 2013-09-25 杭州博林生物技术有限公司 一种苯环利定人工抗原的制备方法
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6355289B1 (ja) * 2017-12-01 2018-07-11 株式会社奥本研究所 有機エレクトロルミネッセンス素子
CN113151188B (zh) * 2021-04-27 2022-10-18 江南大学 一株分泌苯海拉明单克隆抗体的杂交瘤细胞株及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255329A (en) * 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4196185A (en) * 1978-06-05 1980-04-01 Hoffmann-La Roche Inc. Immunoassay for phencyclidine
US4281065A (en) * 1979-01-25 1981-07-28 Syva Company Phencyclidine conjugates to antigenic proteins and enzymes
US4481136A (en) * 1979-09-07 1984-11-06 Syva Company Alkyl substituted fluorescent compounds and conjugates
US4351760A (en) * 1979-09-07 1982-09-28 Syva Company Novel alkyl substituted fluorescent compounds and polyamino acid conjugates
US4588697A (en) * 1979-09-07 1986-05-13 Syntex (U.S.A.) Inc. Method for performing fluorescent protein binding assay employing novel alkyl substituted fluorescent compounds and conjugates
US4593089A (en) * 1980-07-30 1986-06-03 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluorescein aminoglycosides
US4420568A (en) * 1980-07-30 1983-12-13 Abbott Laboratories Fluorescent polarization immunoassay utilizing substituted triazinylaminofluoresceins
AU555213B2 (en) * 1981-02-17 1986-09-18 Abbott Laboratories N-substituted-amido-fluoresein derivatives
US4492762A (en) * 1981-12-11 1985-01-08 Abbott Laboratories Fluorescent polarization immunoassays
US4585862A (en) * 1981-12-11 1986-04-29 Abbott Laboratories Fluorescence polarization immunoassay
US4446065A (en) * 1981-12-22 1984-05-01 Syva Company Phencyclidine compounds and assays for its determination
US4476228A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Determination of unsaturated thyroxine binding protein sites using fluorescence polarization techniques
US4476229A (en) * 1982-11-08 1984-10-09 Abbott Laboratories Substituted carboxyfluoresceins
US4510251A (en) * 1982-11-08 1985-04-09 Abbott Laboratories Fluorescent polarization assay for ligands using aminomethylfluorescein derivatives as tracers
US4681859A (en) * 1984-09-21 1987-07-21 Ortho Diagnostic Systems Inc. Fluorescence polarization immunoassay for heavy antigens
EP0218010A3 (en) * 1985-07-10 1988-01-07 Abbott Laboratories Ligand detection method and substituted carboxyfluorescein tracers therefor
US5221629A (en) * 1986-05-21 1993-06-22 Abbott Laboratories Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies
US5124457A (en) * 1986-05-21 1992-06-23 Abbott Laboratories Phencyclidine and phencyclidine metabolites assay, tracers, immunogens and antibodies
US4939264A (en) * 1986-07-14 1990-07-03 Abbott Laboratories Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
EP0386644B1 (en) * 1989-03-10 1997-06-04 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Reagents for the determination of drugs

Also Published As

Publication number Publication date
EP0459387A3 (en) 1992-09-02
DE69113114T2 (de) 1996-05-02
JPH04235199A (ja) 1992-08-24
US5407834A (en) 1995-04-18
EP0459387A2 (en) 1991-12-04
ES2080188T3 (es) 1996-02-01
CA2043372A1 (en) 1991-11-30
AU643524B2 (en) 1993-11-18
US5155212A (en) 1992-10-13
AU7727291A (en) 1991-12-05
EP0459387B1 (en) 1995-09-20
DE69113114D1 (de) 1995-10-26
ATE128241T1 (de) 1995-10-15

Similar Documents

Publication Publication Date Title
KR910020036A (ko) 펜사이클리딘 및 펜사이클리딘 대사체 검정법, 트레이서, 면역원, 항체 및 시약 키트
EP0399184B1 (en) Reagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay
JP3233285B2 (ja) 冷光分析における放射冷光測定方法
US4476229A (en) Substituted carboxyfluoresceins
US4939264A (en) Immunoassay for opiate alkaloids and their metabolites; tracers, immunogens and antibodies
KR910020438A (ko) 다수염소화된 비페닐을 검출하기 위한 시약 및 방법
JPS62120378A (ja) タンパク質ラベル及び医薬物質放出システム
DE59703499D1 (de) Redoxaktive Verbindungen und deren Anwendung
JPH08504751A (ja) ビオチニル化した化学発光性標識、結合体、測定法及び測定法キット
EP0264797A2 (en) Benzodiazepines assay, tracers, immunogens and antibodies
JPH02227098A (ja) マレイミド基を測定する方法および測定剤
ATE15548T1 (de) Verfahren und reagenz zur bestimmung von creatinin.
KR930703290A (ko) 코티닌 면역검정용 합텐, 트레이서, 면역원 및 항체
US5202270A (en) Cocaine and cocaine metabolites assay tracers, immunogens and antibodies
ES2106040T3 (es) Ensayo para barbituratos, trazadores, inmunogenos, anticuerpos y kit.
FR2518096A1 (fr) Procede et reactifs de determination immunologique par polarisation de fluorescence
EP0373508A3 (en) Barbiturate assay, tracers, immunogens and antibodies
EP0201633A3 (en) Substituted anilide compounds and their use
US5105007A (en) Phenylacetylglutamine (PAG) analytical test
EP0242847A2 (en) Tracers for use in flecainide fluorescence polarization immunoassay
EP0252405A3 (en) 3-methoxy-4-hydroxyphenylglycol fluorescence polarization immunoassay
JPH06324040A (ja) パーオキシダーゼ免疫染色法及び芳香族第一級アミン化合物溶液の安定化方法
JPH07294526A (ja) パーオキシダーゼ免疫染色法及び芳香族第一級アミン化合物溶液の安定化方法
JPH07306203A (ja) パーオキシダーゼ免疫染色法及び芳香族第一級アミン化合物溶液の安定化方法

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application